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MaBACKGROUND Isolated systolic hypertension (ISH), deﬁned as systolic blood pressure (SBP) $140 mm Hg and
diastolic blood pressure (DBP) <90 mm Hg, in younger and middle-aged adults is increasing in prevalence.
OBJECTIVE The aim of this study was to assess the risk for cardiovascular disease (CVD) with ISH in younger and
middle-aged adults.
METHODS CVD risks were explored in 15,868 men and 11,213 women 18 to 49 years of age (mean age 34 years) at
baseline, 85% non-Hispanic white, free of coronary heart disease (CHD) and antihypertensive therapy, from the Chicago
Heart Association Detection Project in Industry study. Participant classiﬁcations were as follows: 1) optimal-normal
blood pressure (BP) (SBP <130 mm Hg and DBP <85 mm Hg); 2) high-normal BP (130 to 139/85 to 89 mm Hg); 3) ISH;
4) isolated diastolic hypertension (SBP <140 mm Hg and DBP $90 mm Hg); and 5) systolic diastolic hypertension
(SBP $140 mm Hg and DBP $90 mm Hg).
RESULTS During a 31-year average follow-up period (842,600 person-years), there were 1,728 deaths from CVD, 1,168
from CHD, and 223 from stroke. Cox proportional hazards models were adjusted for age, race, education, body mass
index, current smoking, total cholesterol, and diabetes. In men, with optimal-normal BP as the reference stratum, hazard
ratios for CVD and CHD mortality risk for those with ISH were 1.23 (95% conﬁdence interval [CI]: 1.03 to 1.46) and 1.28
(95% CI: 1.04 to 1.58), respectively. ISH risks were similar to those with high-normal BP and less than those associated
with isolated diastolic hypertension and systolic diastolic hypertension. In women with ISH, hazard ratios for CVD and
CHD mortality risk were 1.55 (95% CI: 1.18 to 2.05) and 2.12 (95% CI: 1.49 to 3.01), respectively. ISH risks were higher
than in those with high-normal BP or isolated diastolic hypertension and less than those associated with systolic diastolic
hypertension.
CONCLUSIONS Over long-term follow-up, younger and middle-aged adults with ISH had higher relative risk for CVD
and CHD mortality than those with optimal-normal BP. (J Am Coll Cardiol 2015;65:327–35) © 2015 by the American
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ABBR EV I A T I ON S
AND ACRONYMS
BMI = body mass index
BP = blood pressure
CHA = Chicago Heart
Association Detection
Project in Industry
CHD = coronary heart disease
CI = conﬁdence interval
CVD = cardiovascular disease
DBP = diastolic blood pressure
HR = hazard ratio
ICD-8 = International
Classiﬁcation of Diseases-
Eighth Revision
ICD-9 = International
Classiﬁcation of Diseases-Ninth
Revision
IDH = isolated
diastolic hypertension
ISH = isolated
systolic hypertension
SBP = systolic blood pressure
SDH = systolic
diastolic hypertension
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328I solated systolic hypertension (ISH),deﬁned as systolic blood pressure(SBP) $140 mm Hg and diastolic blood
pressure (DBP) <90 mm Hg, is highly preva-
lent in older adults but less so in younger
and middle-aged adults (1–4). Data from the
National Health and Nutrition Examination
Survey indicate that among younger and
middle-aged adults (<40 years of age) in the
United States, the overall prevalence of ISH
between 1988 and 1994 of 0.7% more than
doubled between 1999 and 2004 to 1.6% (2).
From 1988 to 1994, of patients with un-
treated hypertension <50 years of age in the
National Health and Nutrition Examination
Survey, 20% to 30% had ISH (1), which
increased to 40% from 1999 to 2004 (2,4).SEE PAGE 336The clinical consequences of ISH in
younger and middle-aged adults remain un-
certain (5). Whether ISH in younger adults is
“pseudo” or “spurious” hypertension is still
being debated (5–7). Data from a nested case-
control study (insurance actuarial data) andfrom United States and Swedish nationwide cohort
investigations indicate that higher SBP and/or DBP
is associated with higher risk for CVD mortality in
younger adults (8–15). None of these studies, how-
ever, examined the risk by hypertension subtype:
ISH, isolated diastolic hypertension (IDH), and sys-
tolic diastolic hypertension (SDH). Because the Chi-
cago Heart Association Detection Project in Industry
(CHA) study enrolled a large number of younger and
middle-aged adults and their prospective follow-up
encompasses more than 30 years (16,17), it provides
a unique opportunity to investigate these issues.
Using the CHA study data, we assessed whether
ISH in younger and middle-aged adults (18 to 49 years
of age) is associated with higher risk for cardiovas-
cular disease (CVD) mortality compared with normal
blood pressure (BP).
METHODS
STUDY SAMPLE. Between 1967 and 1973, the CHA
study recruited 39,441 participants from Chicago-area
companies and organizations. Details of the study
design and methods have been described (16–18).
Trained staff members obtained a single casual su-
pine BP measurement using a standard mercury
sphygmomanometer. DBP was recorded as Korotkoff
phase V. Heart rate was recorded by electrocardiog-
raphy. Nonfasting serum total cholesterol levels weremeasured using the Levine-Zak method. Diabetes was
deﬁned as clinically diagnosed by a personal physi-
cian or the use of antihyperglycemic medication
(18,19). Questionnaires were used to collect informa-
tion on demographics, smoking, medical history,
and medication use. All participants gave written
informed consent. The study protocol has received
periodic institutional review board approval and, as
described by the Health Insurance Portability and
Accountability Act, the institutional review board
granted a waiver before commencement of the pres-
ent project.
For this study, we identiﬁed participants originally
between 18 and 49 years of age with ascertained vital
status during follow-up (n ¼ 28,238). We excluded
those who had pre-existing coronary heart disease
(CHD), deﬁned as electrocardiographic evidence of
myocardial infarction (n ¼ 20); those on antihyper-
tensive drugs at baseline (n ¼ 599); and 538 additional
participants with missing or incomplete baseline BP
data and/or covariates. As a result, 27,081 participants
were eligible for inclusion.
OUTCOMES ASCERTAINMENT. Vital status was
ascertained through 2003, with an average follow-up
period of 31.1  5.5 years (842,600 person-years). As
previously reported (16,17), before 1979, follow-up
was pursued by direct mail, telephone, contact with
employer, and matching records with Social Security
Administration ﬁles. From 1979 on, the National
Death Index was used to identify deaths. Death cer-
tiﬁcates were obtained and coded by trained research
staff members for multiple causes according to the
International Classiﬁcation of Diseases-Eighth Revi-
sion (ICD-8), and the International Classiﬁcation of
Diseases-Ninth Revision (ICD-9). Mortality from CVD
was deﬁned as ICD-8 and ICD-9 codes 400 to 445,
CHD mortality was deﬁned as ICD-8 and ICD-9 codes
410 to 414, and stroke mortality was deﬁned as ICD-8
and ICD-9 codes 430 to 438.
BP CLASSIFICATION. Participants were stratiﬁed
into 5 mutually exclusive BP categories: 1) optimal-
normal BP (SBP <130 mm Hg and DBP <85 mm Hg);
2) high-normal BP (SBP 130 to 139 mm Hg and DBP 85
to 89 mm Hg, SBP 130 to 139 mm Hg and DBP <85
mm Hg, or SBP <130 mm Hg and DBP 85 to 89 mm Hg);
3) ISH (SBP $140 mm Hg and DBP <90 mm Hg); 4) IDH
(SBP <140 mm Hg and DBP $90 mm Hg); and 5) SDH
(SBP$140 mmHg and DBP$90 mmHg) (20). In a prior
CHA report on the association of BP categories (i.e.,
optimal BP, normal BP, high-normal BP, and stages 1
to 3 hypertension) with 25-year CVD mortality in
young adults (16), there was no difference in CVD
mortality risk between optimal BP and normal BP.
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single BP category, which we deﬁned as the reference
group.
STATISTICAL ANALYSES. All statistical analyses
were performed with SPSS version 18.0J software
(SPSS, Chicago, Illinois). The demographic and clin-
ical characteristics of the participants by sex and hy-
pertension subtype were compared by analysis of
variance and by chi-square tests. We used sex-speciﬁc
Cox proportional hazards models to examine the as-
sociations between hypertension subtype and risk for
mortality from CVD, CHD, and stroke. Unadjusted and
multivariate-adjusted hazard ratios (HRs) and 95%
conﬁdence intervals (CIs) were estimated for each
hypertension subtype. Our analyses were performed
with sequential adjustment. In the ﬁrst step, we car-
ried out unadjusted analyses (model 1). In model 2,
we added age, race/ethnicity (non-Hispanic white,
African American, Hispanic, Asian, and others), and
educational attainment (years) as adjustment
covariates. In model 3, we further adjusted for body
mass index (BMI), smoking, serum total cholesterol,
and diabetes. Statistical signiﬁcance was deﬁned by a
p value <0.05 by 2-sided t test.
RESULTS
DESCRIPTIVE STATISTICS. Of the 27,081 participants
between 18 and 49 years of age, 59% were men,
85% were non-Hispanic white, the mean age was 33.6TABLE 1 Participant Characteristics According to Hypertension Subty
Total
Optimal-Normal BP
(n ¼ 4,261)
Age, yrs 34.3  8.4 33.4  8.1
Ethnicity
Non-Hispanic whites 88.6 87.5
African American 7.4 7.4
Hispanic 2.5 2.8
Asian 0.4 0.6
Other 1.1 1.5
Body mass index, kg/m2 26.3  3.6 25.0  3.1
Current smoker 46.4 44.5
Education, yrs 13.7  2.7 14.1  2.7
Diabetes 1.5 1.6
Serum total cholesterol, mg/dl 196.3  37.8 190.2  36.1
BP, mm Hg
SBP 135.5  16.1 117.5  6.0
DBP 79.5  10.8 71.3  7.1
Heart rate, beats/min* 75.8  12.2 71.5  10.7
Values are mean  SD or %. The p values were obtained by analysis of variance or chi-sq
participants.
BP ¼ blood pressure; DBP ¼ diastolic blood pressure; IDH ¼ isolated diastolic hyperten
hypertension. 9.1 years, and 39% had hypertension at baseline.
Demographic and clinical characteristics of the in-
cluded participants by sex are shown in Tables 1 and 2.
The percents of participants with optimal-normal BP,
high-normal BP, ISH, IDH, and SDH were 26.9%,
24.3%, 25.3%, 3.7%, and 19.8% in men and 52.9%,
21.6%, 12.9%, 2.9%, and 9.7% in women. In both men
and women, those with ISH were less educated and
had a higher proportion of current smoking, higher
mean BMI, higher mean heart rate, and higher
mean total cholesterol level than those with optimal-
normal BP.
BASELINE BP STATUS AND LONG-TERM CVD
MORTALITY. In men, during an average follow-up
period of 30.8 years (489,393 person-years), deaths
numbered 1,318 (269 per 100,000 person-years) from
CVD, 925 (189 per 100,000 person-years) from CHD,
and 145 (30 per 100,000 person-years) from stroke. In
women, during an average follow-up period of 31.5
years (353,206 person-years), deaths numbered 410
(116 per 100,000 person-years) from CVD, 243 (69 per
100,000 person-years) from CHD, and 78 (22 per
100,000 person-years) from stroke. The sex-speciﬁc
Kaplan-Meier cumulative incidence of CVD mortal-
ity, stratiﬁed by hypertension subtype, is shown in
Central Illustration. In both sexes, cumulative CVD
mortality was lowest for those with optimal-normal
BP. In men, the cumulative incidence rate of CVD
mortality in those with ISH was higher compared with
those with optimal-normal BP and was lower than inpe in Men (n ¼ 15,868)
High-Normal BP
(n ¼ 3,854)
ISH
(n ¼ 4,015)
IDH
(n ¼ 589)
SDH
(n ¼ 3,149) p Value
33.6  8.3 33.1  8.4 37.4  7.7 37.4  8.1 <0.001
<0.001
88.7 90.2 86.9 88.2
7.3 6.2 8.5 8.7
2.5 2.2 2.9 2.2
0.3 0.3 0.8 0.2
1.1 1.1 0.8 0.7
25.8  3.2 26.5  3.5 27.1  3.6 28.2  4.1 <0.001
47.2 48.2 43.1 46.5 0.004
13.7  2.6 13.4  2.6 13.3  2.6 13.2  2.7 <0.001
1.1 1.4 3.1 1.7 0.003
193.2  36.6 195.7  37.4 202.6  36.7 208.1  39.3 <0.001
130.5  3.0 145.0  7.6 129.7  4.8 154.6  14.6 <0.001
76.2  6.9 77.8  6.4 90.8  2.2 94.6  7.2 <0.001
75.0  11.4 77.9  11.9 76.0  13.4 80.1  13.0 <0.001
uare tests among hypertension subtypes. *Heart rate was measured by electrocardiography in 13,670
sion; ISH ¼ isolated systolic hypertension; SBP ¼ systolic blood pressure; SDH ¼ systolic and diastolic
TABLE 2 Participant Characteristics According to Hypertension Subtype in Women (n ¼ 11,213)
Total
Optimal-Normal BP
(n ¼ 5,935)
High-Normal BP
(n ¼ 2,419)
ISH
(n ¼ 1,446)
IDH
(n ¼ 328)
SDH
(n ¼ 1,085) p Value
Age, yrs 32.6  10.0 30.8  9.5 32.6  9.9 35.0  10.4 34.8  9.5 39.0  8.9 <0.001
Ethnicity <0.001
Non-Hispanic whites 78.6 76.7 80.4 84.7 73.5 78.2
African American 18.1 19.2 17.5 12.9 21.6 19.1
Hispanic 2.2 2.6 1.6 1.4 3.0 2.0
Asian 0.6 0.8 0.1 0.8 0.9 0.5
Other 0.5 0.7 0.5 0.2 0.9 0.2
Body mass index, kg/m2 23.4  4.2 22.3  3.4 23.6  3.9 24.6  4.5 24.5  4.6 26.6  5.8 <0.001
Current smoker 43.1 43.4 43.0 44.1 43.3 39.9 0.25
Education, yrs 12.7  2.1 12.9  2.1 12.7  2.1 12.4  2.0 12.3  1.9 12.2  2.0 <0.001
Diabetes 1.2 0.9 0.9 1.8 2.1 2.1 <0.001
Serum total cholesterol, mg/dl 189.4  36.8 185.1  35.8 189.1  36.3 194.5  37.0 197.8  37.5 204.5  37.6 <0.001
BP, mm Hg
SBP 126.1  15.7 114.8  7.1 130.2  3.1 144.0  7.1 128.4  5.3 153.9  14.8 <0.001
DBP 74.6  10.9 68.9  7.9 75.6  7.2 77.8  6.3 90.4  1.7 94.8  7.0 <0.001
Heart rate, beats/min* 78.9  12.0 76.6  11.2 80.3  11.7 82.7  12.9 80.5  11.6 83.3  13.4 <0.001
Values are mean  SD or %. The p values were obtained by analysis of variance or chi-square tests among hypertension subtype. *Heart rate was measured by electrocardiography in 10,040
participants.
Abbreviations as in Table 1.
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330those with IDH or SDH. In women, the cumulative
incidence rate of CVD mortality in those with ISH was
higher compared with those with optimal-normal BP
or IDH and was lower than in those with SDH.
Results from Cox proportional hazards models
suggest that among men, ISH was associated with a
higher risk for CVD and CHD mortality compared with
optimal-normal BP (model 1, Table 3). Adjustment for
demographic variables attenuated the associations
(model 2), but ISH remained signiﬁcantly associated
with CVD and CHD mortality with adjustment also for
clinical characteristics including BMI, smoking, total
serum cholesterol, and diabetes (model 3). The
adjusted relative risk for CVDmortality was highest for
SDH (HR: 1.77; 95% CI: 1.49 to 2.09), followed by IDH
(HR: 1.68; 95% CI: 1.29 to 2.17), high-normal BP (HR:
1.25; 95% CI: 1.05 to 1.50), and ISH (HR: 1.23; 95% CI:
1.03 to 1.46). The adjusted HR for CVD mortality asso-
ciatedwith ISH inmen under 40 years of age (n¼ 2,938)
was 1.27 (95% CI: 0.97 to 1.67; p ¼ 0.09), and the HR in
men 40 years of age or older (n ¼ 1,077) was 1.18 (95%
CI: 0.93 to 1.50; p ¼ 0.17); no signiﬁcant interactions
between age (<40 or$40 years) and ISH in association
with CVD mortality risk were found (p ¼ 0.41).
In women, ISH was associated with a higher risk for
CVD and CHD mortality compared with optimal-
normal BP (model 1, Table 3). Adjustment for de-
mographic variables attenuated the associations
(model 2), but ISH remained signiﬁcantly associated
with CVD and CHD mortality with adjustment also for
clinical characteristics (model 3). The relative risk forCVD mortality was highest for SDH (HR: 1.79; 95% CI:
1.36 to 2.37), followed by ISH (HR: 1.55; 95% CI: 1.18 to
2.05). The adjusted HR for CVDmortality risk for ISH in
womenunder 40 years of age (n¼816)was 1.15 (95%CI:
0.63 to 2.10; p¼0.65), and the HR inwomen 40 years of
age or older (n ¼ 630) was 1.68 (95% CI: 1.22 to 2.31; p ¼
0.002); no signiﬁcant interactionswere found between
age (<40 or$40 years) and ISH in associationwith CVD
mortality risk (p ¼ 0.59). In the overall analyses (n ¼
27,081), therewere no signiﬁcant interactions between
sex and ISH in association with CVDmortality risk (p ¼
0.13) and CHD mortality risk (p ¼ 0.29).
In both men and women, ISH was not associated
with stroke risk, with HRs of 1.1 (95% CI: 0.6 to 1.9)
and 1.5 (95% CI: 0.8 to 2.8), respectively. Only SDH
was associated with a higher risk for stroke mortality
independent of demographic and clinical character-
istics, with HRs of 2.4 (95% CI: 1.5 to 3.9) in men and
1.9 (95% CI: 1.0 to 3.6) in women. We analyzed the
association of BP as a continuous variable with CVD
risk. In men, both SBP and DBP were associated with a
higher risk for CVD mortality independent of one
another, while only SBP was associated with CVD
mortality risk in women (Table 4).
DISCUSSION
Our main ﬁndings are that younger and middle-aged
adults (mean age 34 years) with ISH had higher
relative risk for CVD and CHD mortality over 31 years
of follow-up compared with those with optimal-
CENTRAL ILLUSTRATION Hypertension Subtype and Cardiovascular Mortality: Kaplan-Meier Curves of the
Cumulative Incidence of CVD Mortality by Sex
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Sex-speciﬁc cumulative incidence rate of cardiovascular disease (CVD) mortality for each hypertension subtype is shown. The deﬁnition of each
color line is as follows: periwinkle, systolic diastolic hypertension (systolic blood pressure [SBP] $140 mm Hg and diastolic blood pressure
[DBP] $90 mm Hg); gold, isolated diastolic hypertension (SBP <140 mm Hg and DBP $90 mm Hg); violet, isolated systolic hypertension
(SBP $140 mm Hg and DBP <90 mm Hg); green, high-normal blood pressure (BP) (SBP 130 to 139 mm Hg and DBP 85 to 89 mm Hg, SBP
130 to 139 mm Hg and DBP <85 mm Hg, or SBP <130 mm Hg and DBP 85 to 89 mm Hg); salmon, optimal-normal BP (SBP <130 mm Hg and
DBP <85 mm Hg). The log-rank was used to calculate p values. IDH ¼ isolated diastolic hypertension; ISH ¼ isolated systolic hypertension;
SDH ¼ systolic diastolic hypertension.
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331normal BP. In men, the risks associated with ISH were
similar to those in men with high-normal BP and not
as great as those associated with IDH and SDH. In
women, the risks associated with ISH were higher
than those associated with high-normal BP and IDH
and not as great as those associated with SDH.
The proportion of ISH among younger to middle-
aged participants varies by cohort (2% to 8% in all
persons and 14% to 40% in patients with hyperten-
sion) (1–5,21,22). The variation largely relates to dif-
ferences in population characteristics, such as age,
race/ethnicity, and obesity. Our data show that the
prevalence of ISH was 25% in men and 13% in women,
and that one-half of younger men and women withhypertension had ISH. This high prevalence may be
because our cohort included middle-aged adults who
underwent only 1 BP measurement (23). Consistent
with prior reports (1,2,4,5,22,24,25), those with ISH
showed a higher proportion of current smoking, less
education, higher BMI, higher heart rate, and higher
serum total cholesterol levels compared with subjects
with optimal-normal BP.
At least 3 studies have shown prospective associ-
ations between SBP and DBP in young men and future
risk for CVD events; evidence pertaining to younger
women is scarce. A nested case-control study of more
than 45,000 students (mean age 19 years, 93% men)
identiﬁed higher SBP ($130 mm Hg) as a predictor of
TABLE 3 Sex-Speciﬁc Unadjusted and Multivariate-Adjusted HRs (95% CIs) for Risk for CVD Mortality, CHD Mortality, and Stroke Mortality by Hypertension Subtype
Men (n ¼ 15,868) Women (n ¼ 11,213)
Optimal-Normal
BP
High-Normal
BP ISH IDH SDH
Optimal-Normal
BP
High-Normal
BP ISH IDH SDH
CVD mortality
Person-yrs of follow-up 134,247 120,694 124,588 17,741 92,124 188,288 76,827 45,054 10,198 32,839
Number of events
(incidence per
100,000 person-yrs)
221 (165) 276 (229) 282 (226) 79 (445) 460 (499) 139 (74) 73 (95) 82 (182) 13 (127) 103 (314)
Relative risk: HR (95% CI)
Model 1 (unadjusted) 1 (reference) 1.39 (1.16–1.66)‡ 1.39 (1.16–1.65)‡ 2.75 (2.13–3.56)‡ 3.16 (2.69–3.71)‡ 1.00 (reference) 1.28 (0.96–1.70) 2.49 (1.90–3.27)‡ 1.73 (0.98–3.06) 4.37 (3.39–5.64)‡
Model 2 1 (reference) 1.31 (1.10–1.57)† 1.36 (1.14–1.63)† 1.93 (1.49–2.49)‡ 2.16 (1.83–2.54)‡ 1.00 (reference) 1.04 (0.78–1.38) 1.66 (1.26–2.19)‡ 1.21 (0.68–2.13) 2.13 (1.64–2.77)‡
Model 3 1 (reference) 1.25 (1.05–1.50)* 1.23 (1.03–1.46)* 1.68 (1.29–2.17)‡ 1.77 (1.49–2.09)‡ 1.00 (reference) 1.00 (0.75–1.33) 1.55 (1.18–2.05)† 1.05 (0.59–1.85) 1.79 (1.36–2.37)‡
CHD mortality
Number of events
(incidence per
100,000 person-yrs)
152 (113) 200 (166) 203 (163) 55 (310) 315 (342) 71 (38) 39 (51) 60 (133) 9 (88) 64 (194)
Relative risk: HR (95% CI)
Model 1 (unadjusted) 1.00 (reference) 1.46 (1.18–1.81)‡ 1.45 (1.18–1.79)† 2.78 (2.04–3.79)‡ 3.13 (2.58–3.79)‡ 1.00 (reference) 1.34 (0.91–1.98) 3.57 (2.53–5.04)‡ 2.35 (1.18–4.71)* 5.33 (3.80–7.47)‡
Model 2 1.00 (reference) 1.38 (1.12–1.70)† 1.42 (1.15–1.75)† 1.94 (1.43–2.65)‡ 2.13 (1.75–2.59)‡ 1.00 (reference) 1.09 (0.73–1.61) 2.35 (1.66–3.33)‡ 1.62 (0.81–3.25) 2.58 (1.83–3.66)‡
Model 3 1.00 (reference) 1.32 (1.07–1.63)* 1.28 (1.04–1.58)* 1.71 (1.25–2.33)† 1.75 (1.43–2.14)‡ 1.00 (reference) 1.03 (0.70–1.52) 2.12 (1.49–3.01)‡ 1.33 (0.66–2.68) 1.97 (1.36–2.85)‡
Stroke mortality
Number of events
(incidence per
100,000 person-yrs)
24 (18) 26 (22) 26 (21) 6 (34) 63 (68) 28 (15) 17 (22) 14 (31) 1 (10) 18 (55)
Relative risk: HR (95% CI)
Model 1 (unadjusted) 1.00 (reference) 1.20 (0.69–2.09) 1.18 (0.68–2.05) 1.93 (0.79–4.72) 4.05 (2.53–6.49)‡ 1.00 (reference) 1.48 (0.81–2.70) 2.10 (1.11–3.99)* 0.66 (0.90–4.86) 3.77 (2.09–6.82)‡
Model 2 1.00 (reference) 1.14 (0.66–1.99) 1.17 (0.67–2.04) 1.32 (0.54–3.24) 2.74 (1.70–4.41)‡ 1.00 (reference) 1.22 (0.66–2.23) 1.47 (0.77–2.81) 0.47 (0.06–3.44) 1.92 (1.04–3.53)*
Model 3 1.00 (reference) 1.12 (0.64–1.95) 1.08 (0.62–1.90) 1.15 (0.47–2.83) 2.40 (1.46–3.94)† 1.00 (reference) 1.23 (0.67–2.25) 1.46 (0.76–2.82) 0.45 (0.06–3.30) 1.91 (1.01–3.62)*
Sex-speciﬁc unadjusted and adjusted HRs (95% CI) for risk of CVD mortality, CHD mortality, and stroke mortality among each hypertension subtype are shown. As adjustment factors, model 2 includes demographic variables (age at baseline, race, and education), and
model 3 includes demographic variables plus body mass index, current smoking, total cholesterol, and diabetes. Statistical signiﬁcance was deﬁned as p < 0.05. *p < 0.05; †p < 0.01; ‡p < 0.001.
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; CVD ¼ cardiovascular disease; HR ¼ hazard ratio; other abbreviations as in Table 1.
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TABLE 4 Sex-Speciﬁc Unadjusted and Multivariate-Adjusted HR (95% CIs) for BP as
a Continuous Variable for Risk for CVD Mortality, CHD Mortality, and Stroke Mortality
Model
Men (n ¼ 15,868) Women (n ¼ 11,213)
SBP, 10 mm Hg DBP, 5 mm Hg SBP, 10 mm Hg DBP, 5 mm Hg
CVD mortality
Model 1
(unadjusted)
1.26 (1.231.30)‡ 1.25 (1.221.28)‡ 1.37 (1.311.43)‡ 1.28 (1.231.33)‡
Model 2 1.18 (1.151.21)‡ 1.15 (1.131.18)‡ 1.19 (1.131.25)‡ 1.14 (1.091.19)‡
Model 3 1.13 (1.101.17)‡ 1.12 (1.091.15)‡ 1.15 (1.091.21)‡ 1.11 (1.071.17)‡
Model 4 1.06 (1.011.10)† 1.08 (1.051.12)‡ 1.10 (1.021.19)* 1.05 (0.991.12)
CHD mortality
Model 1
(unadjusted)
1.25 (1.201.29)‡ 1.24 (1.201.27)‡ 1.41 (1.331.49)‡ 1.30 (1.241.37)‡
Model 2 1.16 (1.121.20)‡ 1.14 (1.111.17)‡ 1.23 (1.151.31)‡ 1.16 (1.101.23)‡
Model 3 1.11 (1.071.16)‡ 1.10 (1.071.14)‡ 1.17 (1.101.25)‡ 1.12 (1.061.19)‡
Model 4 1.05 (0.9971.10) 1.08 (1.031.12)‡ 1.14 (1.031.25)† 1.04 (0.961.12)
Stroke mortality
Model 1
(unadjusted)
1.39 (1.291.51)‡ 1.38 (1.291.47)‡ 1.35 (1.221.50)‡ 1.27 (1.161.39)‡
Model 2 1.29 (1.191.40)‡ 1.27 (1.191.36)‡ 1.19 (1.061.33)† 1.14 (1.031.26)†
Model 3 1.26 (1.161.37)‡ 1.25 (1.171.35)‡ 1.19 (1.061.34)† 1.14 (1.031.26)*
Model 4 1.08 (0.961.23) 1.19 (1.071.33)† 1.13 (0.951.34) 1.06 (0.921.22)
Sex-speciﬁc unadjusted and adjusted HRs (95% CI) of BP (continuous variable) for risk for CVD mortality, CHD
mortality, and stroke mortality are shown. As adjustment factors, model 2 includes demographic variables (age at
baseline, race, and education) plus SBP (or DBP), model 3 includes demographic variables plus clinical charac-
teristics (body mass index, current smoking, total cholesterol, and diabetes) plus SBP (or DBP), and model 4
includes demographic variables plus clinical characteristics plus SBP plus DBP. Statistical signiﬁcance was deﬁned
as p < 0.05. *p < 0.05; †p < 0.01; ‡p < 0.001.
Abbreviations as in Tables 1 and 3.
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333CHD mortality over the subsequent 50 years (9).
Multivariate adjustments were not performed. In the
second study, of 8,354 male students (mean age 21
years), a 10 mm Hg higher SBP was associated with a
14% higher risk for CVD mortality over a median
follow-up period of 41 years (10). The third study, of a
Swedish nationwide cohort of more than 1.2 million
military men (mean age 18 years), found that higher
SBP or higher DBP was associated with a higher risk
for CVD mortality over a median follow-up period of
24 years (13).
Few studies have assessed CVD risk by hyperten-
sion subtype among younger and middle-aged
adults. Strandberg et al. (26) examined the impact
of ISH on CVD mortality among Finnish men between
30 and 45 years of age (n ¼ 3,267, 32-year follow-up),
but only 17 participants were classiﬁed as having ISH.
Rutan et al. (27) reported that among 317,871 United
States white men between 35 and 57 years of age
(34% were 50 years of age or older), ISH, deﬁned as
SBP $160 mm Hg and DBP <90 mm Hg, was associ-
ated with signiﬁcantly increased risk for CHD mor-
tality (HR: 2.7; p < 0.001) over 6 years of follow-up,
compared with the reference group (those with SBP/
DBP <160/90 mm Hg). The deﬁnition of ISH is not
applicable to current clinical practice, and the refer-
ence group included those with SBP of 140 to 159
mm Hg.
Reasons for the different CVD risks in men with ISH
compared with those with IDH or SDH remain un-
certain. We found that men with ISH were younger
than those with IDH or SDH, suggesting that men with
ISH might have had shorter overall exposure to high
BP. The hemodynamic pattern of ISH has been shown
to vary by individual, involving higher stroke volume
and/or aortic stiffness with normal peripheral
vascular resistance, whereas IDH and SDH had higher
peripheral vascular resistance (3). Hemodynamic al-
terations of ISH in younger adults may be indicative
of a comparatively early clinical stage of hyperten-
sion, that is, a hyperdynamic circulation preceding
the development of higher peripheral vascular resis-
tance (28,29). These hemodynamic characteristics of
ISH may relate to the differences in CVD risks from
those associated with IDH or SDH among men. The
similar CVD mortality risks between high-normal BP,
a predecessor of full-blown hypertension that is
nonetheless associated with atherosclerosis (30), and
ISH in the present study may be interpreted as sup-
porting the concept of ISH in men as a comparatively
early clinical stage of hypertension.
Consistent with prior nationwide United States
survey data (2), 25% of younger and middle-aged
adults with ISH were women. Mechanisms of ISHamong young women are poorly understood. In gen-
eral, women have higher central (aortic) BP, reﬂecting
the pressure experienced by perfused target organs
(e.g., brain, heart, and kidneys), which may therefore
be a better predictor of CVD compared with brachial
BP (31). This reﬂects greater central arterial wave
augmentation and smaller pulse pressure ampliﬁca-
tion than in men (32). Brachial pulse pressure is high
for ISH, so the central BP for ISH, particularly in
women, is expected to be high. Unlike in men, the
CVD mortality risk of ISH in women was greater than
that of high-normal BP in the present study. It re-
mains uncertain if this phenomenon is driven by the
nonsigniﬁcant risk for high-normal BP compared with
optimal-normal BP in women or if the clinical impli-
cations of ISH differ by sex. Unlike in men, high-
normal BP in young and middle-aged women was
not more correlated with CVD mortality risk than
optimal-normal BP in the present study. In the
Framingham Heart Study, although the association of
high-normal BP (vs. optimal BP) with CVD risk was
signiﬁcant in both men and women, this association
was attenuated in women, but not in men, after ad-
justments for comorbidities (33). To assess whether
the association of high-normal BP with CVD risk
differs by sex, especially for younger adults,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The
prevalence of ISH in young and middle-aged adults is
increasing in the United States and is associated with
an increased risk for cardiovascular mortality during
long-term follow-up.
TRANSLATIONAL OUTLOOK: Further studies of
ISH in young and middle-aged adults are warranted to
determine whether antihypertensive drug therapy
could lower cardiovascular risk more than lifestyle
modiﬁcation without medication.
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334etiopathophysiological studies and further analysis
using long-term follow-up studies are warranted.
The CVD mortality risk of ISH was signiﬁcantly
increased in women 40 years of age or older, but not
in those under 40 years of age. The nonsigniﬁcant
results with wider 95% CIs in those <40 years of age
are probably related to their low event rate. The di-
rection of the association between ISH and CVD
mortality risk was the same between those older and
younger than 40 years of age (HRs: 1.68 and 1.15). The
interaction term between age (<40 or $40 years) and
ISH in association with CVD mortality risk did not
achieve statistical signiﬁcance; this difference was
modest.
There was no signiﬁcant association of ISH and
IDH with risk for stroke mortality. Other cohort
studies also reported a lack of association between
higher BP and future risk for stroke mortality in
young adults (11,14). The numbers of stroke deaths
were small compared with those for CHD mortality,
limiting the statistical power of the analyses. In
addition, CHD and stroke may compete as outcomes.
In other words, some individuals would not experi-
ence fatal stroke events, because CHD death had
already occurred.
We analyzed the association of BP as a continuous
variable with CVD risk. In men, both SBP and DBP
were independently associated with a higher risk for
CVD mortality, whereas only SBP was associated with
CVD mortality risk in women. These results are
consistent with the ﬁndings on hypertension pheno-
type risks; that is, ISH, IDH, and SDH are associated
with a higher risk for CVD mortality in men, and ISH
and SDH are associated with a signiﬁcantly higher risk
for CVD mortality in women. The clinical implications
of SBP and DBP and their relative importance (sub-
sequently, ISH and IDH) in younger adults may differ
between men and women (31,32,34). Replication in
different studies and cohorts and further etiopatho-
physiological studies are warranted.
STUDY LIMITATIONS. First, BP values were only from
baseline measurements in the supine position, with
the possibility of misclassiﬁcation and regression-
dilution bias. DBP is especially affected by body
posture, though the inﬂuence of the supine position
on BP is heterogeneous (35,36). In addition, we could
not assess the impact of BP changes and use of anti-
hypertensive medication during follow-up. In aggre-
gate, these factors would tend to underestimate the
true association between BP and CVD risk.
Second, participants from the CHA study were
recruited between 1967 and 1973, before the onset of
the obesity epidemic, so the results do not illuminate
the impact of that epidemic on BP and BP-related risks.Third, because the follow-up duration of the pres-
ent study is very long, competing effects of non-CVD
deaths may be signiﬁcant.
Fourth, the covariate set used in the present
study was limited, and residual confounding (e.g.,
socioeconomic status, diet, alcohol intake, and psy-
chological factors) (2,37–39) may exist.
Finally, our sample consisted largely of non-
Hispanic white participants, so our ﬁndings may or
may not be generalizable to other racial/ethnic groups.
CONCLUSIONS
Among younger and middle-aged adults, those with
ISH were at higher relative risk for CVD and CHD
mortality compared with those with optimal-normal
BP over long-term follow-up. The beneﬁts of drug
treatment for ISH among the elderly have been proved
(40), but such evidence does not exist for younger and
middle-aged adults (41). Our data indicate that ISH in
younger and middle-aged adults is not an innocuous
condition. We cannot deﬁnitively infer whether the
excess CVD risk from ISH in younger and middle-aged
adults warrants antihypertensive drug therapy or
whether only lifestyle modiﬁcation treatment is
necessary. Further research is needed, including
clinical trials and studies seeking better ways (e.g.,
central BP monitoring, biomarkers) to identify
younger and middle-aged adults with ISH who are at
especially greater risk for developing CVD events.
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